Prescribing area | QOF indicatora11 | Drugs (BNF chapter)18 | Max lives saved per 100 000 population13 | Other therapeutic indications for drugs outside QOF indicator definitions (BNF indications)18 |
---|---|---|---|---|
ACE/ARB | CHD11 | ACE/ARB (2.5.5) | 1.5 | Heart failure |
LVD3 | 11.6 | |||
DM15 | 3.4 | |||
Antiplatelet treatment | CHD9 | Aspirin 75mg (2.9) | 24.8 | Prophylaxis of CHD |
Stroke9 | Clopidogrel (2.9) | 15.8 | Peripheral vascular disease | |
Dipyridamole (2.9) | None | |||
Beta blockers | CHD10 | Beta blocker (2.4) | 45.9 | Arrhythmia |
Portal hypertension | ||||
Thyrotoxicosis | ||||
Heart failure | ||||
Anxiety | ||||
Phaechromocytoma | ||||
Diabetes | DM6 | Insulin/hypodermic (6.1.1) | 26.5 | None |
equipment | ||||
DM7 | Oral antidiabetic agent (6.1.2) | 7.4 | ||
Hypertension | CHD6 | Thiazide (2.2.1) | 11.3 | Oedema |
BP5 | Beta blocker (2.4) | 48.2 | (listed above) | |
DM12 | Vasodilator (2.5.1) | 13.5 | Heart failure (hydralazine only) | |
Stroke6 | Centrally acting (2.5.2) | No data | Migraine (clonodine only) | |
Alpha blocker (2.5.4) | Benign prostatic hypertrophy | |||
ACE (2.5.5.1) | (listed above) | |||
ARB (2.5.5.2) | (listed above) | |||
Ca channel (2.6.2) | None | |||
Influenza vaccination | CHD12 | Influenza vaccines (14.4) | 61.6 | Immunosupression |
Stroke10 | 28.1 | Front-line healthcareworkers | ||
DM18 | 63.7 | |||
COPD8 | 25 | |||
Asthma7 | No data | |||
Lipid lowering treatment | CHD8 | Lipid regulating drugs (2.12) | 15.8 | Primary hypercholesterolaemia |
Stroke8 | No data | |||
DM17 | No data | |||
Smoking cessation treatment | CHD4 | NRT | 2.4 | None |
Stroke4 | Bupropion (both part of 4.10) | 1.1 | ||
BP3 | 5.4 | |||
DM4 | 2.4 | |||
COPD5 | 2.6 | |||
Asthma5 | 8.8 |
ACE = angiotensin converting enzyme. ARB = angiotensin receptor blocker.